| (Values in U.S. Thousands) | Dec, 2020 | Sep, 2020 | Jun, 2020 | Mar, 2020 | Dec, 2019 |
| Sales | 20 | 70 | 0 | 20 | 10 |
| Sales Growth | -71.43% | unch | -100.00% | +100.00% | unch |
| Net Income | -32,140 | -21,780 | -20,080 | -18,380 | -15,640 |
| Net Income Growth | -47.57% | -8.47% | -9.25% | -17.52% | -0.39% |
Nantkwest Inc CS (NK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
NantKwest, Inc. is a clinical-stage immunotherapy company. The Company's product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California.